Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
6 International Stocks To buy in July
03:36pm, Friday, 27'th Jun 2025
With over $5 trillion of new investment commitments to date, the U.S.
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
12:11pm, Friday, 27'th Jun 2025
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes
07:08am, Friday, 27'th Jun 2025
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
12:16pm, Thursday, 26'th Jun 2025
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
Novo Nordisk ties up with WeightWatchers to sell Wegovy
11:29am, Thursday, 26'th Jun 2025
Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
11:09am, Thursday, 26'th Jun 2025
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based o
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
03:45am, Thursday, 26'th Jun 2025
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk
Weight loss and diabetes jabs linked to potentially fatal side effect
10:39pm, Wednesday, 25'th Jun 2025
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
Why Shares in Novo Nordisk Lost Weight Today
03:09pm, Wednesday, 25'th Jun 2025
Shares in Denmark's pharmaceutical giant Novo Nordisk (NVO -4.79%) were lower by 4% as of 11 a.m. ET today. The move comes as the fallout from the sudden termination of its partnership with telehealth
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novo Nordisk A/S (“Novo
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
11:14am, Wednesday, 25'th Jun 2025
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.
Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
09:00am, Wednesday, 25'th Jun 2025
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) investors concerning the C
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) on behalf of investors concerning th
Hims & Hers: Here are the risks with the stock after Novo Nordisk terminated its partnership
03:36pm, Tuesday, 24'th Jun 2025
Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
01:01pm, Tuesday, 24'th Jun 2025
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
